SOURCE: Celsion Corporation

Celsion Corporation

June 04, 2012 11:57 ET

Celsion Announces Webcast Interview Featuring Professor Ronnie T.P. Poon

LAWRENCEVILLE, NJ--(Marketwire - Jun 4, 2012) - Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that it has made available its second in a series of "Meet the Investigators" webcast interviews, featuring Ronnie T.P. Poon, MD (QMH), MS, PhD, FRCS (Edin), FACS, Professor of Surgery at the University of Hong Kong, and a Lead Asia Pacific Principal Investigator in Celsion's pivotal Phase III HEAT Study of ThermoDox®, a heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) for the treatment of primary liver cancer. Professor Poon was also a Lead Investigator in Celsion's Phase I clinical study of ThermoDox® in combination with RFA in patients with non-resectable primary and metastatic liver cancer. The interview was conducted at an investor event hosted by Rodman & Renshaw, LLC on June 3, 2012 in Chicago, coincident with the 2012 annual meeting of the American Society of Clinical Oncology taking place on June 1-5, 2012.

Interested parties may access the archived webcast on the Company's website at http://www.celsion.com/events.cfm.

About Celsion Corporation

Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with heat-activated liposomal drug technology. Celsion has research, license, or commercialization agreements with leading institutions including the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, the Kyungpook National University Hospital and the Beijing Cancer Hospital. For more information on Celsion, visit our website: http://www.celsion.com.

Contact Information

  • Investor Contact
    David Pitts
    Argot Partners
    212-600-1902
    Email Contact